3.52
-1.12%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chengdu huasun technology group Inc LTD
Its shares trade on Shenzhen under the ticker 000790.SZ. It has been listed since 27 March 1998. In the fiscal year to 31 December 2025, it reported revenue of CN¥545.5m and a net loss of CN¥320.4m. At that date it held total assets of CN¥1.39bn and shareholders' equity of CN¥715.7m.
Chengdu Huasun Technology Group Inc., Ltd. engages in the development, production, and sale of high-tech products and medicines. The company is headquartered in Chengdu, Sichuan. The firm primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The firm operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Mar 1998
- Employees
- 899
- Website
- huasungrp.com ↗
Leadership
Pay as last reported
- Mr. Mingliang HuangChairman of the Board, since 2020
- Mr. Jun LiChief Financial Officer, Vice President
- Mr. Duoxue WangVice President, Director, since 2020
- Mr. Gang SongVice President
- Mr. Luhong NingSecretary of the Board
- Ms. Yanling HuangDirector
- Mr. Hai LanDirector
- Ms. Ping OuyangDirector, since 2020
- Ms. Ping YangDirector
- Mr. Xudong ChenIndependent Director
- Mr. Daowei MaoIndependent Director
- Ms. Chaoxi ZhuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Chengdu, Sichuan with a focus on the domestic Chinese market.
- Employs 899 full-time employees in the pharmaceutical and technology sectors.
- Offers a diverse range of products including Chinese medicines, Western medicines, and biological drugs.
Weaknesses
- Relies heavily on the domestic Chinese market, particularly Sichuan province.
- Operates primarily in the pharmaceutical industry with limited diversification into other sectors.
- No mention of international market presence or global expansion strategies.
Opportunities
- Potential to expand into international markets beyond the domestic Chinese market.
- Growth opportunities in the pharmaceutical industry within China's healthcare sector.
- Possibility to leverage high-tech product development for new market segments.
Threats
- Dependence on the domestic market may expose the company to regional economic fluctuations.
- Competition within the Chinese pharmaceutical market could increase market pressure.
- Lack of international presence may limit growth in global healthcare trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.